(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Dutch police probe a small blast outside a pro-Israel Christian center - 2Why the Houthis waited until now to strike
- 3First Houthi launch toward Israel since war began triggers alerts across the Negev
- 4Which sandwich do you find totally delectable? !
- 5Hezbollah rockets hit 165 UNIFIL positions in Lebanon while targeting Israel, IDF reveals
- Figure out How to Reveal Stowed away Open Record Rewards
- RFK Jr. says he's following 'gold standard' science. Here's what to know
- 7 Odd Apparatuses to Make Your Party Stick Out!
- 6 US States for Fly Fishing
- The race to mine the moon is on – and it urgently needs some clear international rules
- New 'People We Meet on Vacation' trailer teases Poppy and Alex romance: Everything we know about the new Netflix movie
- The 15 Most Motivating TED Discusses All Time
- These 3 Nail-Free Finds Completely Transformed My Drab Bathroom
- UB professor shares his experience on almost becoming an astronaut
